The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors


the LEAP program

The latest Clinical Trial Evaluation published in Future Oncology discusses the LEAP clinical development program, which is investigating lenvatinib plus pembrolizumab with or without chemotherapy in patients with several solid tumor types who currently have limited available therapies. The LEAP program is based on the promising results from Study 111/KEYNOTE-146 and Study 116/KEYNOTE-524. It includes nine Phase III studies (LEAP-001, LEAP-002, LEAP-003, LEAP-006, LEAP-007, LEAP-008, LEAP-010, LEAP-011 and LEAP-012), each with planned enrolment between 405–950 patients; as well as three Phase II studies (LEAP-004, LEAP-005 and LEAP-009). The authors anticipate that combination therapy with lenvatinib plus pembrolizumab will be an...

To view this content, please register now for access

It's completely free